Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity

Cancer immunology research

Volumn 2, Issue 2, 2014, Pages 142-153

  Redmond, William L ^a   Linch, Stefanie N ^a   Kasiewicz, Melissa J ^a  

^a EARLE A CHILES RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD134 ANTIGEN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; TNFRSF4 PROTEIN, MOUSE;

ADOPTIVE TRANSFER; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CANCER TRANSPLANTATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; EVALUATION STUDY; IMMUNOLOGY; IMMUNOTHERAPY; MALE; MOLECULARLY TARGETED THERAPY; PROCEDURES; PROSTATIC NEOPLASMS; REGULATORY T LYMPHOCYTE; SARCOMA; T LYMPHOCYTE SUBPOPULATION; TRANSGENIC MOUSE;

ADOPTIVE TRANSFER; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CTLA-4 ANTIGEN; CYTOKINES; IMMUNOTHERAPY; MALE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; RECEPTORS, OX40; SARCOMA; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 84996554960     PISSN: None     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-13-0031-T     Document Type: Article

References (0)